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In Pursuit of Profitability and Effectiveness
in the Global Pharmaceutical Industry: Comments
on Professor Walker's Four Challenges
LOUIS LASAGNA,

M.D.*

INTRODUCTION

Despite the remarkable pharmacotherapeutic progress of the last half
century, no informed person doubts that further advances are desperately
needed. Unless they are eradicated by surgery or radiotherapy, most cancers
defy cure.
AIDS continues to kill.
Antibiotic resistance demands
replacements for old antibacterials. Many neurologic diseases are poorly
treatable, and the cruel deterioration caused by Alzheimer's disease is only
slightly amenable to present-day treatment. The list of poorly treatable
diseases is long and daunting. Past progress is no guarantee that future
progress will take place. The seriousness of the challenges facing the global
pharmaceutical industry presented by Professor Walker should not be
underestimated, because today's threats to human health are formidable.
A second given is the considerable variation in health care needs from
country to country. An African nation might most urgently need an adequate
food supply, improved sanitation, and control of malaria-spreading
mosquitoes. Switzerland's health care needs would encompass none of these
and would stress other objectives. This global diversity in public health and
health care needs suggests very strongly that threats to human health implicate
far more than the global pharmaceutical industry.
A third given is more uncomfortable-the World Health Organization's
idealistic goal of "Health for All by the Year 2000" is honorable but
impossible. The "Health for All" rhetoric should not be confused with health
facts all over the world. As the global crisis in emerging infectious diseases'
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and the growing global tobacco pandemic2 demonstrate, populations
worldwide face tremendous threats to their health that appear to overwhelm
not only financial resources but also political will.
The health of every nation is, however, unquestionably dependent
on-among other things-healthy worldwide pharmaceutical and
biotechnology industries that are ready, willing, and able to invest large sums
of money in the search for and delivery of new drugs, medical devices, and
vaccines. Success in these ventures is unpredictable, but failure is guaranteed
without commitment of knowledge and resources. (Luck helps, too.) The
public's health in the global era is, thus, intimately connected to the health of
the global pharmaceutical industry. While discussion of concepts like
profitability and efficiency may seem strange against the backdrop of global
threats to human health, such discussion is not only important but also critical
in evaluating how to fashion responses to global health challenges.
I. THE PROFITABILITY PROBLEM

A fundamental precondition for successful global responses is a profitable
global pharmaceutical industry. Professor Walker has aptly described the need
for pharmaceutical companies to generate sufficient revenue to fund research
and development (R&D) efforts and to provide return on investments to
shareholders.'
While traditional U.S. pharmaceutical companies remain
profitable for the moment (the new biotechnology industry is another matter
and is discussed below), such profitability cannot be taken as a constant.
While making profits is a challenging endeavor in any economic sector in
today's global marketplace, the profitability problem is particularly acute for
pharmaceutical companies that face obstacles in the marketplace, laboratory,
and government bureaucracy.
To begin with, the path from discovery of a new therapeutic compound to
the marketplace is long and treacherous. Only one in every four or five
compounds taken into human subjects receives approval from the U.S. Food
and Drug Administration (FDA), and the average time required to gain such
approval spans from ten to fifteen years. Professor Walker mentioned efforts
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being made to reduce regulatory review times.' However, the situation in the
United States, at least, is somewhat disturbing.
The FDA has indicated a willingness to facilitate early and continuing
collegial discussions between the regulators and the regulated. These
discussions are needed to aid the FDA and pharmaceutical companies in
reaching agreement regarding the key questions and to help them decide how
these key questions should be answered. If such an approach were
comprehensively implemented, the final New Drug Application (NDA) could
become essentially self-reviewing upon filing.
The available data on recent ad hoc conferences between the FDA and the
pharmaceutical companies sponsoring NDAs indicate a certain savings in
regulatory review time, although no drug has ever been handled in the start-tofinish cooperative manner I have in mind. Such conferences also need an
independent appeal mechanism designed to operate in the event of
disagreements between the FDA and the pharmaceutical companies; so that,
if the FDA is unreasonable in its demands, a pharmaceutical company has a
chance to win the argument. Without such an appeal mechanism, a
pharmaceutical company is in the position of debating a 600-pound gorilla in
his cage.
In addition to the time and expense required for the FDA approval process,
the cost of new drug development keeps rising. The average price for the
development of a new drug is now well over $300 million which includes the
costs of failures as well as successes. This staggering figure accounts for both
out of pocket expenses and the "cost of money," which can best be explained
as the amount one could have earned with the money if it were invested so as
to yield undelayed earnings (eight to nine percent is the usual level employed
for these calculations).
As Professor Walker indicated, cost containment is a key driver of the
global pharmaceutical industry today.' However, upward cost pressures also
exist, in connection with both the increasing costs of regulatory approval and
drug development expenditures in the laboratory, pre-clinical research, and
clinical trials. In any industry, cost increases squeeze profitability, unless
revenue growth is also enhanced simultaneously by increases in the market's
size. As Professor Walker noted, the growth in the global market for
pharmaceuticals has slowed dramatically in the 1990s, which underscores the

4. See id at 79-81.
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profitability problem for a global pharmaceutical industry that faces increasing
costs.6
Yet another challenge to profitability is presented by the fact that a new
drug is never simultaneously marketed in the three major markets, the United
States, Europe, and Japan, despite the progress that has been made in the
agreements achieved in the International Conference on Harmonization. 7
These agreements are designed to create a global dossier approach by
eliminating differences among countries in filing formats, requisite data
submissions, and the like.
As Professor Walker rightly indicates,
intergovernmental cooperation on regulatory harmonization is critical for the
future welfare of the global pharmaceutical industry." However, serious
transnational differences remain.
Furthermore, given the egos and cultures of regulatory agencies and varying
national political pressures, these differences are not likely to yield readily to
harmonization. As a result, pharmaceutical companies may have to continue
to bear high costs and delayed revenue streams for securing regulatory
approvals in the major markets-all of which, again, places stress on the
fundamental need for profitability.
An additional problem that ties directly into both the drug development cost
and regulatory approval concerns is how little attention has been paid to the
quantity of data now routinely collected by pharmaceutical companies and
demanded by regulators that could be eliminated without harming the public's
health. A multinational team has recently examined the need for carcinogenic
studies in rats and mice and concluded that mouse data served no additional
usefulness in regulatory judgments over rat data.' This conclusion raises the
reasonable question of whether mouse carcinogenicity studies should be
routinely performed. To adequately address this problem and perhaps alleviate
some of the costs and regulatory burdens on pharmaceutical companies,
cooperative dialogue between the industry and the regulators is required on a
more substantial basis than currently occurs.
Finally, financial pressures within nations present an obstacle for the
pharmaceutical industry. Cost-containment pressures in all countries tend to
attack expenditures on pharmaceuticals as a prime target, despite the fact that

6. Id. at 66-67.
7. ld.at 71-73
8. Id. at 81.
9. J.P.J. Van Oosterhaut et al., The Utility of Two Rodent Species in Carcinogenic Risk Assessment
of Pharmaceuticalsin Europe, 25 REG. TOXICOLOGY AND PHARMACOLOGY 6 (1997).
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drugs represent only a small percentage of any nation's total health care
budget. Furthermore, most countries seem inclined to cap the percentage of
gross national product spent on health care, including pharmaceuticals, despite
the "graying" of the population, which results in a consequent increase in
demand and need for health services.
This is an aspect of the health care environment that cannot be addressed
solely by changes within pharmaceutical companies. National health care
policies in many countries have to be reconsidered-not because they place
pressure on pharmaceutical companies but because they may not serve the
health needs of the citizenry. The rethinking of national health care policies
must take into consideration the views of and pressures facing the
pharmaceutical companies.
II. COST EFFECTIVE OR TRULY EFFECTIVE?
One hears increasingly that drugs should be cost-effective in order to justify
their use. It is difficult to disagree with this concept in the abstract. However,
there is an unwillingness to come to grips with such difficult and painful value
judgments as: "How much is a life worth?" "How much is an added year of
life worth?" "Is the value of a life different for an eighty year-old than it is for
an eighteen year-old?" As far as I can tell, Ceredase, the drug used to treat
Gaucher's disease, is being paid for by U.S. insurance plans despite an
estimated annual cost of $75,000 to $350,000, the average being $160,000 per
year.' ° But what if, rather than a rare disease, Gaucher's disease were a
common one, afflicting millions of patients?
Nor is it necessarily easy to discern the usefulness of a new product at the
time of its launching. Pharmacoeconomic data are increasingly important at
the time a new drug is launched because health maintenance organizations
(HMOs) and hospital formularies are understandably interested in evidence
that a new drug is better, safer, cheaper, or more convenient to take than
currently available medications.
Those on the demand side of the
pharmaceutical market are increasingly under pressure to lower the costs of
providing health care, which affects pharmaceutical companies by forcing
cost-effectiveness to play a larger role in the rationale for developing new drug
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compounds. Gone are the days when pharmaceutical companies could spin off
slight variations of a developed drug and reap good profits from this practice.
However, the true effectiveness of a new drug may not be apparent until one
has the opportunity to study its performance in a "naturalistic" way-in real
clinical practice-as opposed to the inevitably different "hothouse"
environment of the classical controlled trial, with its restrictive inclusion and
exclusion criteria. Compare, for example, the excellent performance of
nicotinic acid in lowering serum cholesterol in pre-marketing controlled trials
with its disappointing post-registration performance, where its unpleasant side
effects are deemed intolerable by perhaps fifty percent of eligible patients.
Furthermore, what about a new drug that is uniquely effective for a
subpopulation but has little effect on most of the population?
Some new pharmaceutical products will save money, but many will not.
What about drugs that "only" make the patient feel better or live longer,
without producing a net savings of dollars? Can we agree on a minimal
"safety net" level of health care for everyone with the burdensome cost of
health care "beyond the net" shared by those willing and able to pay? If so,
how are we to predict the number of such subsidizers so that a drug house can
decide?
For better or worse, the effectiveness of a new drug has to be evaluated on
the basis of the therapeutic contribution it makes to human health, the cost of
the drug to health care providers and patients, and the potential size of the
market for the drug. Finding new drug compounds that deliver significantly
better results in patients, that are cheap to prescribe, and that have a large
market to generate adequate revenues will become an increasingly complicated
challenge for the global pharmaceutical industry.

III. POSSIBLE SOLUTIONS
How helpful are some of the measures initiated by the pharmaceutical
industry to address these problems? Professor Walker discussed the trends
toward both horizontal and vertical integration in the global pharmaceutical
industry." Mergers are logical if they reduce costs, increase productivity,
integrate complementary product lines, or guarantee the existence of adequate
research budgets to support drug innovation. Otherwise, mergers may only
11. Walker, supra note 3, at 68-69.
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increase sales temporarily and gladden the hearts of shareholders or stock
analysts-a consummation not necessarily high on most people's priority list
in the areas of public health and health care. In addition, the increased size of
pharmaceutical companies may in the long run make it more difficult for them
to develop the institutional flexibility to respond to all the challenges facing
pharmaceutical companies.
As for vertical integration, the purchase of pharmacy benefit management
companies (PBMs) by pharmaceutical firms, in theory, could both improve the
quality of prescribing practices and cut costs, while augmenting the revenue
stream for the acquiring company. However, some have questioned the fiscal
wisdom of acquiring some of the bigger PBMs because of their high purchase
price and the possibility of ethical conflicts with bad public relations
reverberations if the company's products are substituted for competitor
products without scientific justification.
In the laboratory, the promises of combinatorial chemistry, "high
throughput screening", computer-aided drug design, and receptorology are also
currently receiving a great deal of attention. To date, however, I believe that
these promises, while rational enough, remain for the most part unfulfilled in
that they have yet to achieve great advances in either cost control or drug
innovation.
The biotech segment of the industry faces its own special problems. It
relies heavily on investment capital which is always impatient for rapid return,
and it must dampen its euphoria as the ease of the earliest compounds-human
insulin, human growth hormone, erythropoietin, and granulocyte colony
stimulating factor-have not been matched by success as the industry moves
into such unknown territories as septic shock and cancer.
CONCLUSION
Can the drug development process in the global era be made more efficient?
How much of the time and money now being spent can be easily eliminated
without risking human health? How many of the problems are representative
of self-inflicted wounds resulting from company error, and how many
represent unreasonable data demands from FDA or other regulatory agencies?
Can national regulatory agencies achieve substantial levels of international
cooperation to facilitate harmonized and more efficient global regulatory
procedures? Will horizontal and vertical integration produce the cost savings
desired along with synergy in innovative capabilities? These questions, and
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many others, suggest that the future of the global pharmaceutical industry is
clouded with uncertainties.
Some of the problems may be inherent in the nature of the business. If the
growing complexity and size of NDA filings with the FDA, for example, are
occasioned by changes in the state of the pharmaceutical art, then no savings
may be possible. However, whether with regard to drug development or the
process of drug regulation, it is hard to believe that perfection has been
achieved.
Ultimately, the importance of a new drug will be determined not by the
novelty of its chemical structure, its mechanism of action, or by the cleverness
of the process for picking drug candidates, but by whether. it represents an
important advance in efficacy, safety, convenience, compliance, and health
care cost savings. A "blockbuster" advance should have little trouble
achieving heart-warming sales in any developed country plagued by the
disease in question. A new drug not so positioned may never pay back the
investment required to bring it to market.
The unsolved therapeutic problems facing medicine are not likely to yield
to solutions without effective collaboration among scientists in government,
academia, and industry, without long-term financial support for biomedical
research (both basic and applied), and without adequate return on investment
for the innovative sector of the pharmaceutical industry. The sorely needed
new products longed for by the sick, their families, and physicians can only be
discovered through persistence and commitment of resources. New drug
development will probably never be speedy or predictable, but success is no
less sweet when achieved despite formidable obstacles.

